Twist Bioscience (TWST) Lowered to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Twist Bioscience (NASDAQ:TWST) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California. “

NASDAQ:TWST traded up $0.06 during trading hours on Wednesday, hitting $21.87. The company’s stock had a trading volume of 33,920 shares, compared to its average volume of 103,332. The company has a quick ratio of 7.43, a current ratio of 7.72 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $610.51 million and a PE ratio of -0.83. Twist Bioscience has a twelve month low of $12.38 and a twelve month high of $34.46.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Tuesday, April 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.03) by $0.10. The company had revenue of $13.56 million for the quarter, compared to analysts’ expectations of $11.88 million. On average, analysts anticipate that Twist Bioscience will post -3.65 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. purchased a new stake in Twist Bioscience during the 4th quarter valued at $31,000. American International Group Inc. purchased a new position in shares of Twist Bioscience during the fourth quarter valued at about $77,000. Deutsche Bank AG purchased a new position in Twist Bioscience in the fourth quarter worth about $151,000. Brandywine Managers LLC purchased a new position in shares of Twist Bioscience during the fourth quarter valued at approximately $462,000. Finally, Asymmetry Capital Management L.P. purchased a new position in shares of Twist Bioscience during the first quarter valued at approximately $550,000. 22.74% of the stock is owned by institutional investors and hedge funds.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Story: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.